Identification of New KCNT1-Epilepsy Drugs by In Silico, Cell, and Drosophila Modeling.

ABSTRACT:

Objective

Hyperactive KCNT1 potassium channels, caused by gain-of-function mutations, are associated with a range of epilepsy disorders. Patients typically experience drug-resistant seizures and, in cases with infantile onset, developmental regression can follow. KCNT1-related disorders include epilepsy of infancy with migrating focal seizures and sleep-related hypermotor epilepsy. There are currently no effective treatments for KCNT1 epilepsies, but suppressing overactive channels poses a potential strategy.

Methods

Using the KCNT1 channel structure we in silico screened a library of known drugs for those predicted to block the channel pore to inhibit channel activity. Cellular KCNT1 channel inhibition was analyzed using electrophysiology and Drosophila bang-sensitive assay

SUBMITTER: Ricos MG 

PROVIDER: S-EPMC12682947 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature